Reporting double-digit growth in the first half of 2019, Krka says it has mined marketing opportunities in new eastern European markets by introducing its established treatments for cardiovascular diseases

Endo has high hope for its pipeline of 505(b)(2) hospital and critical-care drugs in the US as the group looks to return to revenue growth.

Akorn’s second-quarter results show a drop in sales despite the launch of three new products. The company expects a $10m increase in FDA compliance and data-integrity assessment expenditures because of a warning letter issued over its Somerset manufacturing facility.

Three key areas for improvement in in the FDA’s draft guidance on therapeutic protein biosimilars have been highlighted by industry association AAM. Pharmaceutical giants such as Pfizer, Novartis and Celltrion have also expressed concerns highlight shortcomings and sought clarification.

A California Court has secured four major settlements worth $70m with pharmaceutical companies over allegations of entering into collusive pay-for-delay agreements, including two with Teva.

A bipartisan US bill called the Prescription Drug Pricing Reduction Act 2019 aimed at lowering the price of prescription drugs for Americans has passed through the Senate finance committee. The AAM called the legislation “a step in the right direction.”